Gene therapy has come a long way since the initial treatments of the early 1990s, but the insertion of genes can't help diseases with toxic gain-of-function mutations. Apic Bio Inc. is looking to overcome that limitation with its gene therapy platform, Thrive, which includes a second component expressing an miRNA to silence toxic gain-of-function mutations from a single vector.